IMMVF IMV Inc

IMV Leadership to Present Respiratory Syncytial Virus (RSV) Research at RespiDART 2018

IMV Leadership to Present Respiratory Syncytial Virus (RSV) Research at RespiDART 2018

DARTMOUTH, Nova Scotia, Nov. 26, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it will present data on its DPX-RSV program at “” The conference will take place in Miami, Florida, from November 29 - 30, 2018 at the Marriott Miami Biscayne Bay.

Members of IMV’s leadership will share data via an oral presentation as well as a poster session. Details are as follows:

Name:     ‘Evaluation of the therapeutic potential of antibody and T cell targeted immune responses towards RSV Small Hydrophobic protein’
Presenter:Genevieve Weir, PhD, Director of Research, IMV Inc.
 
Oral Presentation:    Oral Abstracts, Session 3
Date:Friday, November 30, 2018
Time:12:00 – 12:10 p.m. ET
Location:Grand Ballroom
 
Poster Presentation:   Abstract #105
Date/Time:November 29 at 3:00 p.m. to November 30 at 6:00 p.m. ET
Location:Salon F & G
  

About RESPIDART

is a new addition to the DART series of healthcare conferences and is focused on drug development challenges and advances for respiratory virus threats to human health. These viruses include long-standing threats such as RSV and influenza, as well as recent outbreaks of MERS-coV, parainfluenza virus, and metapneumovirus. This meeting will focus on advances in therapeutics, vaccinology, virus/host interactions and enzymology, and new study models in development. By bringing together world leaders and key opinion holders, RespiDART 2018 aims to address the latest challenges in vaccine and drug development against respiratory viruses.

About IMV

IMV Inc., formerly Immunovaccine Inc., is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a combination therapy in multiple clinical studies with Incyte and Merck. Connect at .

Contacts for IMV:

MEDIA 

Mike Beyer, Sam Brown Inc.

T: (312) 961-2502 E:

INVESTOR RELATIONS

Pierre Labbé, Chief Financial Officer

T: (902) 492-1819 E:

Patti Bank, Managing Director, Westwicke Partners

O: (415) 513-1284

T: (415) 515-4572 E:

EN
26/11/2018

Underlying

IMMVFIMV Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IMV Inc

Free Trial
IMMVF IMV INC

IMV Inc: 2 directors

Two Directors at IMV Inc bought 120,000 shares at 1.850CAD. The significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...

07/24/21 July 24, 2021 1 EN
 PRESS RELEASE
Free
IMMVF IMV INC

IMV Inc. Announces Pricing of Public Offering

IMV Inc. Announces Pricing of Public Offering DARTHMOUTH, Nova Scotia, March 01, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (“IMV” or the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage immuno-oncology corporation, announced today the pricing of its previously-announced underwritten public offering (the “Offering”) of 4,900,000 common shares at a price to the public of Cdn$5.45 per common share, for aggregate gross proceeds to the Corporation of approximately Cdn$26,705,000 million, before deducting the underwriting discounts and commissions and estimated Offering expenses. In addition, t...

March 1, 2019 1 EN
 PRESS RELEASE
Free
IMMVF IMV INC

IMV Inc. Files Preliminary Prospectus Supplement for Proposed Public O...

IMV Inc. Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares DARTMOUTH, Nova Scotia, Feb. 28, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (“IMV” or the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage immuno-oncology corporation, has today filed a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated June 5, 2018 (the “Base Prospectus”) in connection with a proposed public offering of its common shares (the “Offering”). The Supplement was filed with the securities regulatory authorities in the provinces of Briti...

February 28, 2019 1 EN
 PRESS RELEASE
Free
IMMVF IMV INC

IMV Announces Clinical Update for DPX-Survivac Program in Ovarian Canc...

IMV Announces Clinical Update for DPX-Survivac Program in Ovarian Cancer Following Positive Feedback from U.S. FDA DECIDE phase 2 clinical trial amendment successfully completed with multiple sites now open for enrollment  FDA provided guidance for future registration trial design and for a potential shorter regulatory pathway for developing DPX-Survivac as a monotherapy in certain ovarian cancer patients DARTMOUTH, Nova Scotia, Jan. 29, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced updates on its clinical progra...

January 29, 2019 1 EN
 PRESS RELEASE
Free
IMMVF IMV INC

IMV to Present at 2019 BIO CEO & Investor Conference

IMV to Present at 2019 BIO CEO & Investor Conference DARTMOUTH, Nova Scotia, Jan. 28, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it will participate in the in New York City, NY. This event will take place February 11-12, 2019, at the New York Marriott Marquis. , is scheduled to present a corporate overview and update on Monday, February 11, at 2:45 p.m. ET in the Herald/Soho room. His presentation will be available on IMV’s website at following the meeting.  Now in its 21st year, the BIO CEO & Investor ...

January 28, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch